Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NIDA (National Institute on Drug Abuse) CTN (Clinical Trials Network) Protocol 0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

Next Previous
Search
Trial Profile

NIDA (National Institute on Drug Abuse) CTN (Clinical Trials Network) Protocol 0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupropion (Primary) ; Naltrexone (Primary)
  • Indications Substance-related disorders
  • Focus Therapeutic Use
  • Acronyms ADAPT-2

Most Recent Events

  • 14 Jan 2021 Results (n=403) assessing efficacy and safety of extended-release injectable naltrexone plus oral extended-release bupropion in patients with moderate or severe methamphetamine use disorder published in the New England Journal of Medicine.
  • 14 Jan 2021 Primary endpoint has been met. (Methamphetamine use), according to an Alkermes plc media release.
  • 14 Jan 2021 Results presented in an Alkermes plc media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top